The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | DREAMM-9 final analysis: Bela-VRd shows deep responses in transplant-ineligible myeloma
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the final analysis of the Phase Ib DREAMM-9 trial (NCT04091126) evaluating belantamab mafodotin plus bortezomib, lenalidomide, and dexamethasone (Bela-VRd) in transplant-ineligible patients with newly diagnosed multiple myeloma. Dr Ocio highlights the high response and measurable residual disease (MRD) negativity rates observed with the quadruplet regimen. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
